Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 8/20 | 0.45 |
| ▸ | CA2 | P00918 | 8/20 | 0.45 |
| ▸ | ACHE | P22303 | 8/20 | 0.45 |
| ▸ | MTNR1A | P48039 | 8/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 8/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23923734 | 1.00 | CA1 (0.45) | CA1CA2ACHEMTNR1AMTNR1B | |
| SCHEMBL30062558 | 0.81 | CA1 (0.66) | CA1CA2ACHE | |
| SCHEMBL30061622 | 0.81 | CA1 (0.66) | CA1CA2ACHE | |
| SCHEMBL7450053 | 0.74 | HDAC8 (0.52) | CA1CA2ACHEMTNR1AMTNR1B | |
| SCHEMBL3217014 | 0.74 | CA1 (0.72) | CA1CA2ACHEMTNR1AMTNR1B | |
| SCHEMBL7450046 | 0.74 | HDAC8 (0.52) | CA1CA2ACHEMTNR1AMTNR1B | |
| SCHEMBL1741607 | 0.74 | CA1 (0.50) | CA1CA2ACHEMTNR1AMTNR1B | |
| SCHEMBL20722746 | 0.74 | CA1 (0.50) | CA1CA2ACHEMTNR1AMTNR1B | |
| SCHEMBL20722885 | 0.74 | CA1 (0.50) | CA1CA2ACHEMTNR1AMTNR1B | |
| SCHEMBL17478555 | 0.73 | CA1 (0.41) | CA1CA2ACHEMTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210323975-A1 | CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | VALO EARLY DISCOVERY, INC. | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210323975-A1 | CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | USP28, USP25, USP24 | CA1 1259/4885CA2 2429/4885ACHE 1811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.